Rangeley Capital’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Rangeley Capital’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-97,300	Closed	-$934K	–	109
2024 Q4	$934K	Buy	+97,300	New	+$508K	0.84%	33

Other funds holding PSTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Rangeley Capital's PSTX Position: Q1 2025 in Review

Rangeley Capital sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 97,300 shares — an estimated $934K sold.

Rangeley Capital first reported a position in PSTX in Q4 2024 and held it in 1 quarter. The position peaked at $934K in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

Rangeley Capital reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Rangeley Capital sold 97,300 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $934K.
Rangeley Capital first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2024 and held it in 1 quarter.
Rangeley Capital's Poseida Therapeutics, Inc. Common Stock position peaked at $934K in Q4 2024.
1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Rangeley Capital's 13F filing for Q1 2025, filed 14 May 2025.